Celltrans, Inc.

Lantidra Approved for Brittle Type 1 Diabetes, Offering New Hope for Insulin Independence

- Lantidra, derived from deceased donor pancreas, is the first FDA-approved therapy for brittle type 1 diabetes, addressing severe low blood sugar episodes. - Clinical trials showed that 70% of Lantidra recipients no longer required insulin one year post-transplant, with over 90% experiencing no hypoglycemia. - A clinical trial testing tegoprubart after islet cell transplant shows early signs of success in the first three patients. - Lantidra is available exclusively at UI Health in Chicago for eligible adults with type 1 diabetes meeting specific health criteria.